Category Archives: Psoriasis

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that two abstracts from Dermavants two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, will be presented during the upcoming American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021), on April 23-25, 2021.

Tapinarof is being developed as a novel, once-daily therapeutic aryl hydrocarbon receptor modulating agent (TAMA), cosmetically elegant, steroid-free topical cream for the treatment of plaque psoriasis and atopic dermatitis.

The following posters will be viewable on the conference platform for the entirety of the conference:

Title: Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials

This poster contains secondary efficacy outcomes, including Physician Global Assessment (PGA) scores, percent body surface area (%BSA) affected, and 90% reduction in Psoriasis Area and Severity Index (PASI90) an endpoint more commonly used to assess systemic agents.

Authors: Linda Stein Gold, MD; Andrew Blauvelt, MD, MBA; April Armstrong, MD, MPH; Seemal R. Desai, MD; Howard Sofen, MD; Lawrence J. Green, MD; Stephen K. Tyring, MD, PhD; Laura K. Ferris, MD, PhD; Philip M. Brown, MD, JD; David S. Rubenstein, MD, PhD; Stephen C. Piscitelli, PharmD; Anna M. Tallman, PharmD; Leon Kircik, MD

Title: Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Patient-reported Outcomes from Two Pivotal Phase 3 Trials

This poster contains patient-reported outcomes data, including itch and quality of life measurements.

Authors: Robert Bissonnette, MD; Bruce Strober, MD, PhD; Mark Lebwohl, MD; Jerry Bagel, MD; James Del Rosso, DO; Joseph F. Merola, MD, MMSc; Neal Bhatia, MD; Paul Yamauchi, MD, PhD; Philip M. Brown, MD, JD; David S. Rubenstein, MD, PhD; Anna M. Tallman, PharmD; Stephen C. Piscitelli, PharmD

About Dermavants Phase 3 Program for Tapinarof in Psoriasis

Dermavants pivotal Phase 3 clinical program for tapinarof in adult plaque psoriasis consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980), as well as PSOARING 3 (NCT04053387), the ongoing long-term safety study.

PSOARING 1 and PSOARING 2, which collectively enrolled 1,025 patients, were two identically designed, multi-center, randomized, vehicle-controlled, double-blind, parallel group studies conducted in North America that evaluated the safety and efficacy of tapinarof cream, 1% dosed once daily (QD) for 12 weeks versus vehicle QD in adult patients aged 18-75 years diagnosed with plaque psoriasis. The primary endpoint of both studies was a PGA score of clear (0) or almost clear (1) with a minimum 2-grade improvement from baseline at Week 12.

PSOARING 3 is a long-term, open-label, extension study to evaluate the safety and efficacy of tapinarof cream, 1% for the treatment of plaque psoriasis in adults. Subjects in the study had previously completed treatment with tapinarof or vehicle in either the PSOARING 1 or PSOARING 2 Phase 3 pivotal efficacy and safety studies. PSOARING 3 consists of up to 40 weeks of tapinarof cream, 1%, and a 4-week safety follow-up period. As such, subjects who received drug during PSOARING 1 and PSOARING 2, completed PSOARING 3 having received treatment with tapinarof cream for up to 52 weeks. Greater than 90% of eligible patients who completed PSOARING 1 and PSOARING 2 enrolled in PSOARING 3.

About Psoriasis

Psoriasis is a chronic, systemic, inflammatory skin disease characterized by red patches and plaques with silvery scales on the skin. Psoriasis affects approximately 8 million people in the United States and 125 million worldwide.

Psoriasis can begin at any age, but typically has two peaks of onset, the first at age 20 to 30 years and the second at age 50 to 60 years. People with psoriasis are at an increased risk of developing other chronic and serious health conditions. Comorbidities include psoriatic arthritis, inflammatory bowel disease, hypertension, diabetes, obesity, and depression. Psoriasis has a significant impact on quality of life and on psychological health.

About Dermavant

Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavants focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development. The companys robust medical dermatology pipeline includes both late-stage and earlier-stage-development product candidates the company believes could address important immuno-dermatological conditions, including psoriasis, atopic dermatitis, vitiligo, primary focal hyperhidrosis, and acne. Dermavant is developing its lead product candidate, tapinarof (DMVT-505), as a novel therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of plaque psoriasis and atopic dermatitis, which affect approximately 8 million and 26 million people in the United States, respectively. The company reported positive Phase 3 results for tapinarof cream in adult patients with plaque psoriasis. For more information, please visit http://www.dermavant.com, and follow us on Twitter (@dermavant) and LinkedIn (Dermavant Sciences).

Read more here:
Dermavant Announces Tapinarof Data Presentations at the AAD VMX 2021 - Business Wire

This article was originally published here

Am J Clin Dermatol. 2021 Apr 16. doi: 10.1007/s40257-021-00603-w. Online ahead of print.

ABSTRACT

The emergence of data from clinical trials of biologics, the approval of new biologics, and our improved understanding of psoriasis pathogenesis have increased the therapeutic possibilities for the treatment of moderate-to-severe psoriasis. Biologics currently approved for the treatment of psoriasis include tumor necrosis factor inhibitors, interleukin (IL)-17 inhibitors, ustekinumab (an IL-12/23 inhibitor), and IL-23 inhibitors. Data from clinical trials and studies of the safety and efficacy of biologics provide essential information for the personalization of patient care. We discuss the benefits and disadvantages of biologics as a first-line treatment choice, update treatment recommendations according to current evidence, and propose psoriasis treatment algorithms. Our discussion includes the following comorbid conditions: psoriatic arthritis, multiple sclerosis, congestive heart failure, inflammatory bowel disease, hepatitis B, nonmelanoma skin cancer, lymphoma, and latent tuberculosis. We make evidence-based treatment recommendations for special populations, including pediatric patients, patients with coronavirus 2019 (COVID-19), and pregnant and breastfeeding patients with psoriasis. Ultimately, individualized recommendations that consider patient preferences, disease severity, comorbid conditions, and additional risk factors should be offered to patients and updated as new trial data emerges.

PMID:33861409 | DOI:10.1007/s40257-021-00603-w

Read this article:
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review - DocWire News

This article was originally published here

Int J Clin Pharmacol Ther. 2021 Apr 16. doi: 10.5414/CP203906. Online ahead of print.

ABSTRACT

OBJECTIVE: To determine the relative effectiveness and safety of doses of secukinumab and guselkumab in patients with active psoriatic arthritis (PsA).

MATERIALS AND METHODS: A Bayesian network meta-analysis was performed incorporating data from randomized controlled trials (RCTs) to evaluate the effectiveness and safety of secukinumab 150 mg, secukinumab 300 mg, and guselkumab 100 mg every 4 weeks (Q4W) and guselkumab every 8 weeks (Q8W).

RESULTS: Six RCTs, including 2,385 patients, fulfilled the inclusion criteria. The surface under the cumulative ranking curve (SUCRA) revealed that secukinumab 300 mg had the highest probability of reaching a 20% American College of Rheumatology (ACR20) response rate, followed by secukinumab 150 mg, guselkumab 100 mg Q4W, guselkumab 100 mg Q8W, and placebo. The ACR50 response rate revealed the same distribution pattern as the ACR20 response rate. The SUCRA rating, dependent on the psoriasis area and severity index of at least 75% (PASI75) response rate, showed that guselkumab 100 mg Q4W had the highest possibility of achieving the PASi75 response, followed by guselkumab 100 mg Q8W, secukinumab 300 mg, secukinumab 150 mg, and placebo. Safety analyses focused on serious adverse events (SAEs), adverse events (AEs), and withdrawals attributable to AEs that did not have statistically relevant variation in the respective intervention categories.

CONCLUSION: Based on the ACR20 and ACR50 response rates, secukinumab 300 mg had the strongest response effectiveness, whereas guselkumab 100 mg Q4W was the most effective treatment strategy for PsA based on PASI75. However, there was little disparity between the treatment options with regard to SAEs.

PMID:33860750 | DOI:10.5414/CP203906

View post:
Relative efficacy and safety of secukinumab and guselkumab for the treatment of active psoriatic arthritis: A network meta-analysis - DocWire News

In patients with active psoriatic arthritis (PsA), treatment with tofacitinib is associated with long-term efficacy (up to 36 months) and safety (up to 48 months), according to results of an analysis published in Lancet Rheumatology.

Researchers sought to evaluate the long-term safety and efficacy of tofacitinib in adult patients with active PsA.

The open-label, long-term extension study the final analysis of the Oral Psoriatic Arthritis Trial (OPAL) Balance study (ClinicalTrials.gov Identifier: NCT01976364) was conducted at 124 centers in 16 countries.

Continue Reading

Primary study endpoints included incidence of clinical laboratory abnormalities, changes from baseline in laboratory parameters up to 48 months in patients from the long-term extension study and substudy, and incidence and severity of adverse events (AEs). Eligible patients in OPAL Balance study had also participated in the OPAL Broaden or the OPAL Beyond phase 3 trials.

In the OPAL Balance study, all participants received open-label tofacitinib 5 mg twice daily, with dose escalations to 10 mg twice daily at month 1 for inadequate symptom control, as well as reductions to 5 mg twice daily thereafter for safety. All participants could continue to receive concomitant treatment with specific conventional synthetic disease-modifying antirheumatic drugs. Eligible patients could also enter the randomized, double-blind methotrexate withdrawal substudy, in which participants received open-label tofacitinib 5 mg twice daily plus either masked methotrexate or masked placebo.

A total of 686 participants were enrolled in OPAL Balance study, between February 17, 2014, and March 28, 2016, who received treatment with tofacitinib and were enrolled in the all-tofacitinib group for the safety and efficacy analyses. Ultimately, 66% (n=453) of participants completed this study and 34% (n=233) discontinued their participation in either the long-term extension study or the methotrexate withdrawal substudy. In the all-tofacitinib group, the mean duration of tofacitinib treatment was 794.6 days and the total duration of treatment was 1492.4 person-years in the long-term extension study. Mean age of the participants in the all-tofacitinib group was 48.8 years; 54% of the participants were women; mean duration of PsA was 7.6 years.

Up to month 48, 84% (n=574) of participants reported the occurrence of all-cause AEs, with 17% experiencing serious AEs and 11% discontinuing treatment because of an AE. Overall, 6 patients died, among whom 1 was within the risk period (incidence of death was 0.1 patients with events [95% CI, 0.0-0.3] per 100 person-years). Incidences of AEs of special interest, which was defined as the number of patients with events per 100 person-years, included the following: 1.7 (95% CI, 1.2-2.5) for herpes zoster; 1.0 (95% CI, 0.6-1.6) for serious infections; 0.4 (95% CI, 0.1-0.8) for opportunistic infections; 0.7 (95% CI, 0.4-1.2) for malignancies other than nonmelanoma skin cancer (NMSC); 0.9 (95% CI, 0.5-1.5) for NMSC; 0.2 (95% CI, 0.1-0.6) for major adverse cardiovascular events; 0.4 (95% CI, 0.1-0.8) for arterial thromboembolism; and 0.1 (95% CI, 0.0-0.3) for pulmonary embolism. Efficacy was sustained for up to 36 months.

A major limitation of the current study included the lack of generalizability to patients who are new to tofacitinib treatment. Further, the long-term extension study was open-label and had no placebo group; the analyses used observed values; and evaluations of dose-related effects were conducted post hoc.

Researchers concluded that the data reported in this trial support the use of tofacitinib in the long-term treatment of active [PsA].

Disclosure: This analysis was supported by Pfizer. Please see the original reference for a full list of authors disclosure.

Nash P, Coates LC, Fleishaker D, et al. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. Lancet Rheumatol. 2021;3:270-283. doi:10.1016/S2665-9913(21)00010-2

See the original post:
Long-Term Efficacy and Safety of Tofacitinib in Patients With Psoriatic Arthritis Analyzed - Rheumatology Advisor

Up Market Research (UMR) has included a latest report on the Global Psoriasis Therapeutics Market into its archive of market research studies. The report is an amalgamation of detailed market overview based on the segmentations, applications, trends and opportunities, mergers and acquisitions, drivers, and restraints. The report showcases the current and forthcoming technical and financial details of the Psoriasis Therapeutics market. The research study attracts attention to a detailed synopsis of the market valuation, revenue estimation, and market statistics. The study on the emerging trends in the global and regional spaces on all the significant components, such as market capacity, cost, price, demand and supply, production, profit, and competitive landscape. The report also explores all the key factors affecting the growth of the global market, consisting of the demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

Some of the major companies that are covered in this report:

Astellas Pharma Inc.AstraZeneca plcBoehringer Ingelheim GmbHF. Hofffmann-La RocheGlaxoSmithKline plcMerck & Co.Inc.Valeant Pharmaceuticals InternationalInc.Biocon LimitedEli Lilly and CompanyG & W Laboratories Inc.

*Note: Additional companies can be included on request

Get a free exclusive sample report of Psoriasis Therapeutics market @ https://www.upmarketresearch.com/home/requested_sample/11821

Impact of COVID-19

The report also talks about the impact of the ongoing global crisis i.e., COVID-19 on the Psoriasis Therapeutics market and explains how the future is going to unfold for the global market. Our analysts have researched thoroughly about the effects of the pandemic on the global economy. The outbreak has directly affected production and demand disrupted the demand and supply chain. The report also computes the financial impact on firms and financial markets. Up Market Research (UMR) has accumulated insights from several delegates of the industry and got involved in the primary and secondary research to offer the clients data & strategies to combat the market challenges during and after the COVID-19 pandemic.

Highlights of the report:

Our research analysts who are the building blocks of the company have worked extensively to fabricate the research report which will give that extra edge to our clients business in the competitive market. The market research report can be customized as per you and your needs. This means that Up Market Research (UMR) can cover a particular product, application, or can offer a detailed analysis in the report. You can also buy a separate report for a specific region.

You can buy the complete report in PDF format: @ https://www.upmarketresearch.com/buy/psoriasis-therapeutics-market

The market scenario is likely to be fairly competitive. To analyze any market with simplicity the market is fragmented into the following segments:

By Applications:

OralParenteralTopical

By Types:

TNF InhibitorsPDE4 InhibitorsInterleukin BlockersOthers

By Regions:

Segmenting the market into smaller components helps in analyzing the dynamics of the market with more clarity. Another key component that is integrated into the report is the regional analysis to assess the global presence of the Psoriasis Therapeutics market. You can also opt for a yearly subscription of all the updates on the Psoriasis Therapeutics market.

If you have any questions on this report, feel free to reach us! @ https://www.upmarketresearch.com/home/enquiry_before_buying/11821

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Psoriasis Therapeutics Market Overview

Global Psoriasis Therapeutics Market Analysis and Forecast by Type

Global Psoriasis Therapeutics Market Analysis and Forecast by Application

Global Psoriasis Therapeutics Market Analysis and Forecast by Sales Channel

Global Psoriasis Therapeutics Market Analysis and Forecast by Region

North America Psoriasis Therapeutics Market Analysis and Forecast

Latin America Psoriasis Therapeutics Market Analysis and Forecast

Europe Psoriasis Therapeutics Market Analysis and Forecast

Asia Pacific Psoriasis Therapeutics Market Analysis and Forecast

Asia Pacific Psoriasis Therapeutics Market Size and Volume Forecast by Application

Middle East & Africa Psoriasis Therapeutics Market Analysis and Forecast

Competition Landscape

About Up Market Research (UMR):

Up Market Research (UMR) has a vast experience in making customized market research reports in a number of industry verticals. We strive for complete client satisfaction. We cover in-depth market analysis, which consists of stipulating lucrative business strategies, especially for the new entrants and the emerging players of the market. Our team makes sure that each report goes through intensive primary, secondary research, interviews, and consumer surveys before final dispatch.

We invest in our analysts to ensure that we have a full roster of experience and expertise in any field we cover. Our team members are selected for stellar academic records, specializations in technical fields, and exceptional analytical and communication skills. We also provide ongoing training and knowledge sharing to keep our analysts tapped into industry best practices and loaded with information.

Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]search.comWebsite https://www.upmarketresearch.comAddress 500 East E Street, Ontario, CA 91764, United States.

https://neighborwebsj.com/

Read the original post:
Psoriasis Therapeutics Market 2021 Will Reflect Significant Growth in Future with Size, Share, Growth, and Key Companies Analysis- Astellas Pharma...

The promising drug pipeline will further propel the demand for the advanced medication in the long run. This trend is expected to propel over the forecast period as the prevalence rate has been increasing. Hence, a thorough understanding approach is required for disease management, which would certainly help manage childhood psoriasis better. However, lack of awareness in emerging economies and insufficient research funding may hamper the market.

The global Pediatric Psoriasisreport studies the prudent tactics undertaken by the leading market players, such as partnerships and collaborations, mergers & acquisitions, new product launches, and joint ventures. The global Pediatric Psoriasisis highly consolidated due to the presence of a large number of companies across this industry. These companies are known to make hefty investments in research and development projects. Also, they control a considerable portion of the overall market share, thus limiting the entry of new players into the sector.

To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/pediatric-psoriasis-market

The global Pediatric Psoriasisstudy covers the current COVID-19 scenario that has turned the global business sphere upside down. The coronavirus has resulted in a major economic downturn worldwide, while also adversely impacting the growth of this industrial sector. The pandemic has brought about drastic changes in market conditions. Therefore, the latest report elaborates on the rapidly changing market scenario and conducts preliminary, as well as the future assessment of COVID-19 impact on the market. Moreover, the document contains a broad analysis of prime aspects of the market, with expert opinions on the current market standing and historical data.

Key highlights of the Global Pediatric Psoriasisreport:

See the original post:
Pediatric Psoriasis Market Compound Annual Growth Rate of 21.38% | Market Trend Growing demand for biologics and natural remedies for child...

C4X Discoverys business model, of out-licensing rather than developing projects in house, looks like it is starting to deliver. This weekthe UK group announced a 414m ($494m) biodollar licensing deal with Sanofi for its oral preclinical IL-17A inhibitor programme. While the upfront payment of 7m was slightly more modest, landing a big name partner was enough help drive shares in the UK biotech up by 8%.

The deal with Sanofifollows an agreement with Indivior in 2018, worth$10m up front,and is all part of a plan by C4X's chief executive, Clive Dix, to hand off assets before they even hit the clinic. Speaking to Evaluate Vantage he said: We think our technology is best placed finding molecules, getting good quality starting points, taking them as far as we can as a candidate and out licensing.

This approach runs counter to that of many UK biotechs, which have traditionally focused on discovering single products usually due to funding constraints and trying to commercialise them. It is an method that Mr Dix thinks might have held some companies back.

We try to avoid thisbecause if your first molecule fails it kills the company, and if it doesnt it changes the company completely, because you then become that molecule, he says.

Shifting the risk

In C4Xs deal with Sanofi, the French company will take on all of the risks and cost of commercialising the oral IL-17 inhibitor, which will be developed initially in psoriasis.

The current leading IL-17 inhibitor forpsoriasis, Novartis's Cosentyx,sold almost $3bn for this use last year, but as a MAb it tends to be reserved for more severe forms of the disorder.

C4X is hoping its small molecule approach will allow the treatment model to move back to milder forms of psoriasis, giving themand Sanofia bigger share of the market, which is forecast to hit $32bn in 2026, according to Evaluate Pharma.

Alongside the 7m upfront payment from Sanofi, C4X is in line for a further 11m if a candidate enters the clinic. The money will be ploughed back into C4Xs current pipeline, which includes a Nrf-2 activator and an oral 47 integrin inhibitor programme, in the hopes of finding partners for these assets. Mr Dix is also on the lookout for another project to bring in to keep the number of internal programmes running at about five.

The deal with Sanofi has brought some renewed investor interest in the company, whose shares had hit historic lows earlier this year. But at 43p the stock isstill a long way off the 130p it hit in 2016, making C4X look relatively cheap.

Staying single

ButMr Dix is not interested in selling anytime soon. The end goal is to make this a sustainable drug discovery engine. Roll forward five or six years and if we have done another three deals, then you have an expectation of revenues coming in all the time and its a fairly chunky business.

And it is gaining scale through deals that generate revenues that Mr Dix hopes will keep C4X independent. All the little [UK] companies that have done well have been bought in the main by an American [group]and disappeared, he says.

Mr Dix blames theinability of UK firms to grow independently on the age-old problem of lack of funding in the country. If there was the right sort of risk-reward funding then we might build a company that becomes the next Celltech or the next Amgen, but the funding model doesnt work at the moment, it just doesnt want to put big money behind clinical development candidates, he says.

As such C4X will have to keep signing more deals with big pharma if it wants to buck the UK biotech trend.

Read more from the original source:
C4X shows being early to the party can bring success - Vantage

Jess Wright has admitted that dealing with her uncle's tragic death has made her psoriasis get worse.

The former TOWIE star, 35, has always been honest with fans about her skin condition - something she's been battling for 14 years.

And it seems as though it's only gotten worse after she was forced to endure major heartbreak when her uncle Edward died from coronavirus.

The reality TV star said that although it's been frustrating to see her psoriasis worsen during the last "really rubbish few months", Jess admits she's glad she was honest with fans.

"My psoriasis has got a lot worse because of the pandemic. With my uncle and all the stress of the past year, it's flared up. It's been a really rubbish few months with everything that's gone on," she told new! mag.

"I'm really glad I did share it. So many people appreciate my openness and it's important to keep it real," Jess added.

Psoriasis is an autoimmune disease that turns skin red, dry and itchy.

Jess last month opened up about how "broken" her beloved uncle's death has left her.

"Broken," Jess began in her social media tribute.

"It still doesnt seem real that youre gone. You leave the biggest hole in our familys heart because you were everything that represented the Wrights & you did everything you could to keep us together as much as possible as it meant so much to you.

Jess continued: "Not just my uncle, but like a second dad to me in so many ways."

She went on: "The best grandad, dad, husband, son & uncle there ever could be. Your smile lights up every room & you are the glue that held us all together.

"I will look after nanny & grandad just like you did so well, I promise. And your children who I love like my own brothers and sister.

"I miss you so much already Ed, see you again some day. Love you uncle Eddie," Jess concluded in her touching message.

Do you have a story to sell? Get in touch with us at webcelebs@trinitymirror.com or call us direct 0207 29 33033

Original post:
Jess Wright says coping with heartache of uncle's tragic death made her psoriasis worse - Mirror Online

Simple tasks become difficult during flares, and I can lose my train of thought mid-sentence, which makes me feel really self-consciousespecially at work. I worry that people take this as me being rude and not concentrating, but really its just the psoriatic arthritis brain fog and fatigue kicking in. Jude D., 28

Fatigue is a huge part of what we are up against. Tired doesnt really explain it. Everything creates more fatigue, including stress, pain, and medication changes. And just because I feel great today and we make plans, tomorrow I might wake up feeling like Im under a cloud of exhaustion, and Im just too tired to move. There is no way to know when it is going to happen.

Most of us dont complain about our pain daily. If we are bringing it up, its because its bad! I dont always talk about my drug changes, but when a drug fails, I will be unmedicated for months as I switch to a new one. During this time, Im in more pain, and probably pretty emotional. Tanya G., 43

My psoriasis is not visible to others, and the days Im really struggling with my arthritis, I dont leave my house. So when people see me, they think Im fine. Its been a roller coaster of good days and bad, but nobody sees the bad days when you cant get out of bed. I really find that lack of understanding to be the hardest part of an invisible illnessjust because you dont appear sick doesnt mean that you are not sick.

I used to be quite active, and its difficult to not be able to do what I used to do. Psoriatic arthritis strips you of your identity, but you eventually build yourself back up, learn to live with it, and accept that things will be different. For example, I love to travel, but I now travel very differently. Im more conscious of burnout and fatigue, and I make sure I have lots of time to rest and dont push myself to the limit. But I refuse to let psoriatic arthritis control my life or hold me back. Brenda S., 35

When I was diagnosed, I remember feeling so sad. I went from running three or more miles a day to barely being able to walk for the first four hours of my day. I remember being so stiff and in so much pain at work because standing or sitting for too long hurt. Im a nurse and for a while I was afraid I wasnt going to be able to work anymore. Night shifts threw me into flares and I had to go way out of my comfort zone to ask for accommodations.

I think the grief roller coaster is the hardest part of living with psoriatic arthritis. You have to give up a lot, and once you think youve given up everything you can think of, something else comes along that you suddenly cant do anymore. A lot of times, you havent finished grieving one thing and before you know it, another thing pops up to grieve. It takes a toll on your mental health.

Having psoriatic arthritis has been such a wild ride, and sometimes I resent the ride, but the community that Ive been so privileged to meet through this on social media is something I am so incredibly grateful for. Jenny P., 27

I began running about three years ago, with a goal to run a 5k. I got hooked and that goal soon moved to a 10k, a half-marathon, and then finally a marathon. My running journey was going well, and I was improving quite quicklyuntil just over a year ago when I suddenly developed swelling in my ankles and wrists and became very fatigued.

One of my biggest worries when I was diagnosed with psoriatic arthritis was that I would have to stop running. But my rheumatologist told me to keep being as active as I could. Funnily enough, I can run with minimal pain in my joints, but peeling vegetables and scrubbing the shower can result in hours of dull aches in my wrists and hands. So even though my rheumatologist may not have meant that I should train for another marathon, this is exactly what I did! I became quite determined that psoriatic arthritis wouldnt stop me from achieving this goal, and although I had to take a few weeks off from training now and then, I managed to complete many months of training and ran my marathon in September of last year. Tracy U., 44

Related:

Link:
6 People Living With Psoriatic Arthritis Share Their Stories - Self

SAN DIEGO, March 30, 2021 /PRNewswire/ --Dermata Therapeutics, Inc., a privately held biotechnology company, announced today that it has dosed its first patient in a Phase 1b trial of DMT310 for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, consisting of a once-weekly topical treatment with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin diseases. The Phase 1b trial will enroll 30 mild-to-moderate psoriasis patients who will receive once-weekly treatments of DMT310 for 12 weeks at 3 clinical sites across the United States.

"Enrolling the first patient in this psoriasis study is a big step towards potentially providing these patients with an effective and safe topical product that only needs to be applied once per week, as there are few effective options for patients with milder disease," states Christopher Nardo, PhD, Dermata's SVP, Development. "We believe that DMT310 could offer a differentiated topical treatment of psoriasis with its once weekly application schedule, combined with its multiple mechanisms of actions to treat the multiple symptoms of psoriasis."

DMT310-006 Trial Design:DMT310-006, is a 12-week, multi-center, open-label, proof of concept trial designed to evaluate the safety, tolerability and efficacy of once-weekly dosing of DMT310 in 30 mild-to-moderate psoriasis patients. Patients will receive 12 once-weekly topical treatments of DMT310 and be observed for 12 weeks. The primary endpoints include the Physician's Global Assessment, the Investigator's Psoriasis Area Severity Index and the Pruritis Visual Analog Scale at week 12. Dermata expects to have top-line results in the second half of 2021.

About DMT310: DMT310 is a naturally derived product candidate derived from a unique freshwater sponge that is harvested under specific environmental conditions and then processed into a powder. The powder is mixed with fluidizing agent immediately prior to application and only needs to be applied once per week. DMT310's organic components contain chemicals components that when tested in vitro, have shown a dose dependent inhibition of both IL-17A and IL-17F, which are believed to be major effector cytokines in the pathogenesis of psoriasis.

About Dermata: Dermata is a clinical-stage biotechnology company focused on making major advancements in the treatment of medical and aesthetic skin diseases and conditions. Dermata has a team of experienced individuals who are currently focused on progressing two programs for the treatment of acne, psoriasis, rosacea and aesthetic indications. To learn more about Dermata and its pipeline of product candidates, please visit http://www.dermatarx.com.

CONTACT: Dermata ContactSean ProehlInvestor Relations858-800-2543 Ext. 705 [emailprotected]

SOURCE Dermata Therapeutics, Inc.

http://www.dermatarx.com

Read more:
Dermata Therapeutics Announces Initiation of a Phase 1b Trial of the Once-Weekly Topical Application of DMT310 for the Treatment of Mild-to-Moderate...